Global Glucagon Delivery Device Market Overview:
Global Glucagon Delivery Device Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2026-2035, Considering the Base Year As 2025.
Global Glucagon Delivery Device Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2026-2035, with base year as 2025. This research study of Glucagon Delivery Device involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Glucagon Delivery Device Market:
The Glucagon Delivery Device Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Glucagon Delivery Device Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Glucagon Delivery Device Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Glucagon Delivery Device market has been segmented into:
Injectable Glucagon
Nasal Glucagon
Oral Glucagon
By Application, Glucagon Delivery Device market has been segmented into:
Severe Hypoglycemia
Type 1 Diabetes
Type 2 Diabetes
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Glucagon Delivery Device market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Glucagon Delivery Device market.
Top Key Players Covered in Glucagon Delivery Device market are:
BD
Tandem Diabetes Care
Ypsomed
Nipro Corporation
Zealand Pharma A/S
Valeritas
Pharmacia Upjohn
Medtronic
Terumo Corporation
Roche Diabetes Care
Xeris Pharmaceuticals Inc
Insulet Corporation
Eli Lilly and Company
Novo Nordisk
Abbott Laboratories
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Glucagon Delivery Device Market Type
4.1 Glucagon Delivery Device Market Snapshot and Growth Engine
4.2 Glucagon Delivery Device Market Overview
4.3 Injectable Glucagon
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.3.3 Injectable Glucagon: Geographic Segmentation Analysis
4.4 Nasal Glucagon
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.4.3 Nasal Glucagon: Geographic Segmentation Analysis
4.5 Oral Glucagon
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.5.3 Oral Glucagon: Geographic Segmentation Analysis
Chapter 5: Glucagon Delivery Device Market Application
5.1 Glucagon Delivery Device Market Snapshot and Growth Engine
5.2 Glucagon Delivery Device Market Overview
5.3 Severe Hypoglycemia
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.3.3 Severe Hypoglycemia: Geographic Segmentation Analysis
5.4 Type 1 Diabetes
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.4.3 Type 1 Diabetes: Geographic Segmentation Analysis
5.5 Type 2 Diabetes
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.5.3 Type 2 Diabetes: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Glucagon Delivery Device Market Share by Manufacturer (2023)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 BD
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 TANDEM DIABETES CARE
6.4 YPSOMED
6.5 NIPRO CORPORATION
6.6 ZEALAND PHARMA A/S
6.7 VALERITAS
6.8 PHARMACIA UPJOHN
6.9 MEDTRONIC
6.10 TERUMO CORPORATION
6.11 ROCHE DIABETES CARE
6.12 XERIS PHARMACEUTICALS INC
6.13 INSULET CORPORATION
6.14 ELI LILLY AND COMPANY
6.15 NOVO NORDISK
6.16 ABBOTT LABORATORIES
Chapter 7: Global Glucagon Delivery Device Market By Region
7.1 Overview
7.2. North America Glucagon Delivery Device Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Injectable Glucagon
7.2.2.2 Nasal Glucagon
7.2.2.3 Oral Glucagon
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Severe Hypoglycemia
7.2.3.2 Type 1 Diabetes
7.2.3.3 Type 2 Diabetes
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Glucagon Delivery Device Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Injectable Glucagon
7.3.2.2 Nasal Glucagon
7.3.2.3 Oral Glucagon
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Severe Hypoglycemia
7.3.3.2 Type 1 Diabetes
7.3.3.3 Type 2 Diabetes
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Glucagon Delivery Device Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Injectable Glucagon
7.4.2.2 Nasal Glucagon
7.4.2.3 Oral Glucagon
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Severe Hypoglycemia
7.4.3.2 Type 1 Diabetes
7.4.3.3 Type 2 Diabetes
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Glucagon Delivery Device Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Injectable Glucagon
7.5.2.2 Nasal Glucagon
7.5.2.3 Oral Glucagon
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Severe Hypoglycemia
7.5.3.2 Type 1 Diabetes
7.5.3.3 Type 2 Diabetes
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Glucagon Delivery Device Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Injectable Glucagon
7.6.2.2 Nasal Glucagon
7.6.2.3 Oral Glucagon
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Severe Hypoglycemia
7.6.3.2 Type 1 Diabetes
7.6.3.3 Type 2 Diabetes
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Glucagon Delivery Device Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Injectable Glucagon
7.7.2.2 Nasal Glucagon
7.7.2.3 Oral Glucagon
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Severe Hypoglycemia
7.7.3.2 Type 1 Diabetes
7.7.3.3 Type 2 Diabetes
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Glucagon Delivery Device Scope:
|
Report Data
|
Glucagon Delivery Device Market
|
|
Glucagon Delivery Device Market Size in 2025
|
USD XX million
|
|
Glucagon Delivery Device CAGR 2025 - 2032
|
XX%
|
|
Glucagon Delivery Device Base Year
|
2024
|
|
Glucagon Delivery Device Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
BD, Tandem Diabetes Care, Ypsomed, Nipro Corporation, Zealand Pharma A/S, Valeritas, Pharmacia Upjohn, Medtronic, Terumo Corporation, Roche Diabetes Care, Xeris Pharmaceuticals Inc, Insulet Corporation, Eli Lilly and Company, Novo Nordisk, Abbott Laboratories.
|
|
Key Segments
|
By Type
Injectable Glucagon
Nasal Glucagon
Oral Glucagon
By Applications
Severe Hypoglycemia
Type 1 Diabetes
Type 2 Diabetes
|
